

## Bioinformatics Institute (BII)

# Protein Sequence Analysis

Executive Director  
**MAURER-STROH Sebastian**

Research Scientist  
**LIMVIPHUVADH Vachiranee**

Senior Post-Doctoral Research  
Fellow  
**KENANOV Dimitar**

Senior Post-Doctoral Research  
Fellow  
**HO Wei-Hao Joses**

Senior Post-Doctoral Research  
Fellow  
**MAK Tze Minn Sandy**

Post-Doctoral Research Fellow  
**CHONG Cheng Shoong Ken**


Research Manager  
**LEE Tze Chuan Raphael**

Senior Research Officer  
**XU Yani Angela**

Research Officer  
**MIYAJIMA Jhoann**

Research Officer  
**CHEW Yi Hong**

Research Officer  
**MAKHEJA Meera**






Viruses



Restricted

### Computational Sequence and Structure Analysis





```
...AGCAAAAGCAGGGGAAAACAAAAGCAATCAAAAATGAAGGC
AATACTAGTAGTTCTGCTATAACATTGCAACCGCAAATGCA
GACACATTATGTATAGGATACAGCCBAACAATCAACAGACA
CTGTAGACACAGTACTGAAATAATATAACAGTAACACACTC
TGTTAACCTTCTAGAAATACATAACGGGAAACTATGCA...
```

Food flavors



Drugs

Human variation



Product Safety



We are working at the interface between sequence and structure




Viruses



Restricted

Computational  
Sequence and  
Structure Analysis




```
...AGCAAAAGCAGGGGAAAACAAAAGCAATCAAAAA  
AATACTAGTAGTTCTGCTATAACATTTGCAACCGG  
GACACATTATGTATAGGATACACCCBAACAATTCA  
CTGTAGACACAGTACTGCAAAATAATATAACAGTAAAGGATG  
TGTTAACCTTCTAGAAATTAACATACCGGGAAACTATGCA...
```

Food flavors



Drugs

Human variation



Product Safety



Enzymes can be used to naturally produce food flavours and fragrances but also drugs!

# AI (CNN) prediction of mutation effects on enzyme function

**Kinetics**

EVB Model

**Binding**

Docking scores  
Binding free energy

r=0.9

**Stability**

Yasara + FoldX vs Rosetta

8 of 12 correct predictions of increased stability (incl. top 3)

PHARMA INNOVATION  
PROGRAMME SINGAPORE (PIPS)



**Aggregation** Tango  
Waltz

1 predicted mutation set increases solubility 2-fold


**Allostery** Allosigma

7 of 14 correct predictions of long range binding effect

**Sequence Conservation**

SIFT  
Shannon entropy

Jump from 11% good sites to 67% good sites






Viruses



Restricted

### Computational Sequence and Structure Analysis



Food flavors




Drugs

...AGCAAAAGCAGGGGAAAACAAAAGCAATCAAAAATGAAGGC  
AATACTAGTAGTTCTGCTATAACATTGCAACCGCAAATGCA  
GACACATTATGTATAGGATACACCCBAACAATTCAACAGACA  
CTGTAGACACAGTACTGAAATTAATGTAACAGTAACACCTC  
TGTTAACCTTCTAGAAATTAACATACCGGGAAACTAT


Human variation



Product safety




Proteins can cause allergy if similar to other allergens.



# Computational prediction of protein allergenicity: from viruses to shampoo and food safety

## Path to new impacts:

- Started with flu antibody binding modelling expertise
- New industry application of similar method applied to antibody binding of allergens in consumer care products
- New area of application in food safety assessment




**AllerCatPro**  
predicts if a protein is similar to known allergens

## The impact:

- ✓ Industry:
  - ✓ 4 RCAs long-term work with P&G for co-development
  - ✓ active use by P&G in product development safety pipeline
  - ✓ Gluten extension work with The Coca Cola Company
- ✓ Supporting SG 30-by-30 goal by providing tool to assess risk of alternative/novel protein sources for food
  - ✓ Project with CSIRO/JCU on seafood allergy and risk of insect proteins as food source
  - ✓ Consulting for Singapore Food Agency for ongoing safety assessments in expert panel

**Accuracy benchmark**  
(allergens vs non-allergens with same structure fold)





Viruses



Restricted

### Computational Sequence and Structure Analysis



Food flavors



Human variation

gsk  
MSD  
Pfizer

GIS

Individual mutations can cause disease or affect drug efficacy

Product Safety




# SNPdrug3D database for Precision Medicine

```

...AGCAAAAGCAGGGGAAAACAAAAGCAA
CAAAAATGAAGGCAATACTAGTAGTTCTG
CTATATACATTTGCAACCGCAAATGCAGA
CACATTATGTATAGGTTATCATGCGAACAA
TTCAACAGACACTGTAGACACAGTACTAG
AAAAGAATGTAACAGTAACACACTCTGTTA
ACCTTCTAGAAGACAAGCATAACGGGAAA
CTATGCA...
    
```

Sequence SNP/variant X



You have variant X that could affect response to drug A so I suggest drug B!



Good, thanks!



User	Value
Scientist	SNP prioritization VUS annotation
Clinician scientist	SNP prioritization VUS annotation Known and new PGx SNPs
Clinician	Known PGx SNPs

[https://commons.wikimedia.org/wiki/File:Doctor\\_with\\_Patient\\_Cartoon.svg](https://commons.wikimedia.org/wiki/File:Doctor_with_Patient_Cartoon.svg)

# SNPdrug3D database for Precision Medicine



- Benign
- Damaging
- VUS
- Mapped to structure
- Not mapped to structure
- Mapped to drug
- Not mapped to drug

# SNPdrug3D database for Precision Medicine



CREATING GROWTH, ENHANCING LIVES

**SNP DRUG**

Search: chr10-94775393-T-C

CYP2C19 Gene Name

Submit

Search overview

Terms: CYP2C19

Results:

Chrom	Gene	Ref	Alt	AP	RefP	Transcripts	Proo	Pre	Palt	Sib	Poly	Gene
chr10	94775185	A	T	6.57540e-06	NP_000760.1	ENSP00000360372, P33261	99	H	L	tolerated(0.22)	benign(0.003)	CYP2C19
chr10	94775185	A	T	6.57540e-06	P33261	ENSP00000360372, P33261	99	H	L	tolerated(0.22)	benign(0.003)	CYP2C19
chr10	94775185	A	T	6.57540e-06	ENSP00000483...	ENSP00000483847, AO4087...	99	H	L	tolerated_low_e...	benign(0)	CYP2C19
chr10	94775185	A	T	6.57540e-06	NP_000760.1	NP_000760.1	99	H	L	tolerated(0.22)	benign(0.003)	CYP2C19
chr10	94775194	T	C	1.97202e-05	NP_000760.1	ENSP00000360372, P33261	102	L	P	deleterious(0)	possibly_damaging(...)	CYP2C19
chr10	94775194	T	C	1.97202e-05	P33261	ENSP00000360372, P33261	102	L	P	deleterious(0)	possibly_damaging(...)	CYP2C19
chr10	94775194	T	C	1.97202e-05	NP_000760.1	NP_000760.1	102	L	P	deleterious(0)	possibly_damaging(...)	CYP2C19
chr10	94775393	T	C	6.57307e-06	NP_000760.1	ENSP00000360372, P33261	112	I	T	deleterious(0)	probably_damaging(...)	CYP2C19
chr10	94775393	T	C	6.57307e-06	P33261	ENSP00000360372, P33261	112	I	T	deleterious(0)	probably_damaging(...)	CYP2C19
chr10	94775393	T	C	6.57307e-06	ENSP00000483...	ENSP00000483847, AO4087...	112	I	T	deleterious_low...	possibly_damaging(...)	CYP2C19
chr10	94775395	G	A	0.000749527	NP_000760.1	ENSP00000360372, P33261	113	V	I	tolerated(0.99)	benign(0.001)	CYP2C19
chr10	94775393	T	C	6.57307e-06	NP_000760.1	NP_000760.1	112	I	T	deleterious(0)	probably_damaging(...)	CYP2C19
chr10	94775395	G	A	0.000749527	P33261	ENSP00000360372, P33261	113	V	I	tolerated(0.99)	benign(0.001)	CYP2C19
chr10	94775395	G	A	0.000749527	ENSP00000483...	ENSP00000483847, AO4087...	113	V	I	tolerated_low_e...	benign(0)	CYP2C19
chr10	94775399	T	G	6.57289e-06	NP_000760.1	ENSP00000360372, P33261	114	F	C	deleterious(0)	probably_damaging(...)	CYP2C19
chr10	94775395	G	A	0.000749527	NP_000760.1	NP_000760.1	113	V	I	tolerated(0.99)	benign(0.001)	CYP2C19
chr10	94775399	T	G	6.57289e-06	P33261	ENSP00000360372, P33261	114	F	C	deleterious(0)	probably_damaging(...)	CYP2C19
chr10	94775399	T	G	6.57289e-06	NP_000760.1	NP_000760.1	114	F	C	deleterious(0)	probably_damaging(...)	CYP2C19
chr10	94775416	T	C	0.00157144	NP_000760.1	ENSP00000360372, P33261	120	W	R	deleterious(0)	probably_damaging(1)	CYP2C19
chr10	94775416	T	C	0.00157144	P33261	ENSP00000360372, P33261	120	W	R	deleterious(0)	probably_damaging(1)	CYP2C19
chr10	94775416	T	C	0.00157144	ENSP00000483...	ENSP00000483847, AO4087...	120	W	R	deleterious_low...	probably_damaging(1)	CYP2C19
chr10	94775416	T	C	0.00157144	NP_000760.1	NP_000760.1	120	W	R	deleterious(0)	probably_damaging(1)	CYP2C19
chr10	94775427	C	G	1.31513e-05	NP_000760.1	ENSP00000360372, P33261	123	I	M	tolerated(0.41)	benign(0.036)	CYP2C19
chr10	94775427	C	G	1.31513e-05	P33261	ENSP00000360372, P33261	123	I	M	tolerated(0.41)	benign(0.036)	CYP2C19
chr10	94775427	C	G	1.31513e-05	ENSP00000483...	ENSP00000483847, AO4087...	123	I	M	tolerated_low_e...	benign(0.074)	CYP2C19

**SNP DRUG**

Search: chr10-94775393-T-C

Structure feature viewer

**Structure feature viewer**

Structure: CYP2C19

Chain: A

Drug: Voriconazole

Feature: 112: I>T: AF: 0.00000657

Colors: Chain Drug Feature

Controls: Drug List, Pocket List, Struct View, Drug View, Pocket SNPs

Labels: Feature, Pocket SNPs, All SNPs



Save As: File Name: voriconazole.png

Buttons: Activate, Transparent, Box, Scale, Save as


**PDB Structures**

100-50% Identity	90-50% Identity	80-70% Identity	70-50% Identity	60-50% Identity	50-40% Identity	Method	HRPind	AlphaFold
1og2_A_HIC 94.7	106_A - 87.25	106_A - 71.91	106_A_CIS 60.43	106_A_CIS 59.43	106_A - 59.25	106_A_CIS 59.43	106_A - 1.055	
1og2_B_HIC 94.7	106_A_DMS 87.29	106_A_CIS 71.91	106_A_CIS 69.43	106_A_CIS 69.43	106_A - 59.25	106_A_CIS 59.43	106_A - 0.243	
1og2_A_HIC 94.7	106_A_DF 87.29	110_A_COU 70.91	110_A_COU 70.91	106_A_CIS 69.43	106_A - 59.25	106_A_CIS 59.43	106_B - 0.214	
1og2_A_SIV 94.7	106_A_PAM 87.92	110_C_COU 70.91	110_C_COU 70.91	106_B_CIS 69.43	106_D - 59.25	106_B_PAM 44.94	106_A - 0.174	
1og2_B_HIC 94.7	106_B_PAM 87.92	110_C_COU 70.91	110_C_COU 70.91	106_B_CIS 69.43	106_A_PAM 44.94	106_A_PAM 44.94	106_A - 0.161	
1og2_B_SIV 94.7	106_A_SCR 87.92	110_D_COU 70.91	110_D_COU 70.91	106_C_CIS 69.43	106_B_PAM 44.94	106_B_PAM 44.94	106_A_DMS 0.239	
106_A_P 95.32	106_A_PAM 87.92	111_A_BMO 70.91	111_A_BMO 70.91	106_D_CIS 69.43	106_A - 50.91	106_C_PAM 44.94	106_A - 0.156	
106_A - 99.79	106_B_SCR 87.92	111_B_BMO 70.91	106_E_CIS 69.43	106_A - 50.91	106_D_PAM 44.94	106_A - 0.156	106_A - 0.156	
106_A - 99.79	106_B_PAM 87.92	111_C_BMO 70.91	106_F_CIS 69.43	106_A_V03 59.95	106_A - 44.38	106_A - 0.156	106_A - 0.156	
106_C - 99.79	106_A_MTX 87.92	111_D_BMO 70.91	106_A - 69.43	106_B_V03 59.95	106_A - 44.38	106_A - 0.156	106_A - 0.156	
106_A - 99.79	106_A_PAM 87.92	106_A_TVH 71.91	106_A - 69.43	106_A_OV 59.95	106_A - 44.38	106_A - 0.156	106_A - 0.156	
106_A - 94.7	106_A_PAM 87.92	106_A_CIS 71.91	106_A - 69.43	106_B_OV 59.95	106_A - 44.38	106_A - 0.156	106_A - 0.156	
106_B - 94.7	106_B_PAM 87.92	106_A_PAM 87.92	106_B - 69.43	106_B_V03 59.95	106_A - 44.38	106_A - 0.156	106_A - 0.156	

# SNPdrug3D database for Precision Medicine



Ken



Chris Tan team




GIS



Viruses

Restricted

Computational  
Sequence and  
Structure Analysis



```

...CAGGGGAAAACAAAAGCAACAAAATGAAGGC
AA...GTTCTGCTATAACATTGCAACCGCAAATGCA
GAP...BTATAGGATACACCCBAACAATTCAACAGACA
CTGTAGACACAGTACTCAAA...AATCTAACAGTAACACACT
TGTTAACCTTCTAGAAATCAACATAACGGGAAACTATGCA...


```

Food flavors



Drugs


Human variation



Product Safety



Long history of flu  
work but COVID put  
us into the spotlight



Our BII team is part of the history of this pandemic and a pillar of GISAID and in Singapore's COVID response





*Curation:* Shruti, Yi Hong, Meera *Annotation, tools, reports:* Raphael, Yani, Jose, Sandy, Dimitar, Ken

# Real-time genomic data sharing during the COVID-19 Pandemic


*GISAID's transparent sharing mechanism is favored over anonymous sharing via public-domain*

enabled first vaccines (Polack et al *N Engl J Med* 2020)  
enabled first diagnostic tests (Bohn et al *Clin Chem Lab Med* 2020)

In SG: Contributed to Fortitude and Resolute kits



Genome Sequences from 210 Countries & Territories



- 4,200 institutions entrust data to GISAID
- 50,000 participating researchers
- primary source of hCoV-19, influenza and RSV data

BII with help from GIS has started and complemented the global team that curated all genomes on GISAID since day 1 and every single genome goes through our servers for error checking and mutation annotation



# Our tool enables real-time primer tracking for Dx



POWERING DISCOVERIES



▼ Basic Filters

Primers ⊕

Primer Type ⊕





Countries ⊕

Charite-RdRP x | ▼

Specify Type | ▼

Filter Countries | ▼

► More Settings



Download Map Data


E.g. the team alerted for mismatches in China CDC N and Charite RdRP primers when they emerged

Charite-RdRP	EPI_ISL_1807318	hCoV-19/Australia /ACT0100/2021	<table border="0"> <tr> <td>G</td><td>T</td><td>G</td><td>A</td><td>A</td><td>A</td><td>T</td><td>G</td><td>G</td><td>T</td><td>C</td><td>A</td><td>T</td><td>G</td><td>T</td><td>G</td><td>T</td><td>G</td><td>G</td><td>C</td><td>G</td><td>G</td> </tr> <tr> <td> </td><td> </td> </tr> <tr> <td>G</td><td>T</td><td>G</td><td>A</td><td>A</td><td>A</td><td>T</td><td>G</td><td>G</td><td>T</td><td>C</td><td>A</td><td>T</td><td>G</td><td>T</td><td>G</td><td>T</td><td>G</td><td>G</td><td>C</td><td>A</td><td>G</td> </tr> </table>	G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	G	G																							G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	A	G	fwd
G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	G	G																																																	
G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	A	G																																																	
Charite-RdRP	EPI_ISL_2107499	hCoV-19/Australia /NSW-R0238/2021	<table border="0"> <tr> <td>G</td><td>T</td><td>G</td><td>A</td><td>A</td><td>A</td><td>T</td><td>G</td><td>G</td><td>T</td><td>C</td><td>A</td><td>T</td><td>G</td><td>T</td><td>G</td><td>T</td><td>G</td><td>G</td><td>C</td><td>G</td><td>G</td> </tr> <tr> <td> </td><td> </td> </tr> <tr> <td>G</td><td>T</td><td>G</td><td>A</td><td>A</td><td>A</td><td>T</td><td>G</td><td>G</td><td>T</td><td>C</td><td>A</td><td>T</td><td>G</td><td>T</td><td>G</td><td>T</td><td>G</td><td>G</td><td>C</td><td>A</td><td>G</td> </tr> </table>	G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	G	G																							G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	A	G	fwd
G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	G	G																																																	
G	T	G	A	A	A	T	G	G	T	C	A	T	G	T	G	T	G	G	C	A	G																																																	




# CoVsurver real-time surveillance for mutations that can affect vaccines etc.

Raphael



Building on the FluSurver success since the 2009 pandemic, the BII team built the CoVsurver that can help to find and interpret relevant changes in the virus.

The tool is used since early 2020 and has been crucial for GISAID curation and annotation ever since.



### Spike S477N

Key to alternative position numbering:

477	hCoV-19 numbering
464	SARS numbering

Chosen reference: Spike hCoV-19/Wuhan/WIV04/2019

Position in reference: 477  
AA in reference: S  
AA in query: N

Mutation Spike S477N already occurred 4128 times (3.98% of all samples with Spike sequence) in 6 countries. The first strain with this mutation, collected in 2020, was hCoV-19/Australia/VIC5321/2020. The mutation most recently occurred in strain hCoV-19/Australia/NSW-SAVID-2752/2020, collected in September 2020. ([see map](#))

[See detailed global statistics for this position](#)

A mutation at the position equivalent to Spike 477 has been reported in the literature to be related to [Host Changes and Others](#).

As seen in resolved structures of proteins from related strains, the Spike position equivalent to this mutation is involved in:

- [Antibody Recognition Sites](#)
- [Host Cell Receptor Binding](#)
- [Viral Oligomerization Interfaces](#)

[PubMed search for this mutation](#)



**NEW:** [Occurrence and phylogenetic context of mutation at CoV-GLUE](#)  
[Phylogenetic context for this mutation at Nextstrain](#)

Protein: Spike  
Coronavirus type: Yeast SARS-CoV-2 (2019)  
Mutation (as in paper): S477N  
neutral AA: S  
neg. eff. AA: N  
Effect: Host Change

**Receptor binding**

**Comment:**  
In a deep mutational scanning experiment that expresses Spike RBD in a yeast-display platform, S477N mildly increases the binding to ACE2 (apparent dissociation constant delta-log10 value: 0.06)  
[Literature reference](#)  
(Mutation S477N in the paper is at an equivalent position of the mutation in your query)

**Antibody interaction:** The mutation position (red atoms) corresponds to position 477 on viral chain E (yellow backbone) of protein entry 6xnn, originating from Severe acute respiratory syndrome coronavirus 2 and with a label of Spike glycoprotein. The mutation is within 6 Å from antibody chain F (purple backbone).





1,680 variant phenotype annotations from literature plus 3,826 3D interactions





# Example for early phase of Delta and Omicron

## Flashback Apr 2021



Our team saw relevant changes in strains in India and alerted INSACOG and SG research teams before the strain exploded (it later got named Delta)



Winston  
Yani,  
Raphael

Variant tracker built by BII team on GISAID homepage

Most recent reported occurrences in different countries

Country	Strain Name	Collection Date
Australia	hCoV-19/Australia/NSW-RPAH-1933/2021	2021-11-27
Belgium	hCoV-19/Belgium/rega-20174/2021	2021-11-24
Botswana	hCoV-19/Botswana/R43B70_BHP_4021000195/2021	2021-11-23
South Africa	hCoV-19/South Africa/CERI-KRISP-K032284/2021	2021-11-23
Italy	hCoV-19/Italy/LOM-Sacco_Var_T96348/2021	2021-11-22
United Kingdom	hCoV-19/England/MILK-2B67570/2021	2021-11-21
Israel	hCoV-19/Israel/SMC-7022800/2021	2021-11-20
Hong Kong	hCoV-19/Hong Kong/VM21045145/2021	2021-11-18

Country Submission Count

Country	Total #GR/484A (B.1.1.529)	#GR/484A (B.1.1.529) in past 4 weeks	%GR/484A (B.1.1.529) in past 4 weeks
South Africa	99	99	69.7
Botswana	19	19	18.6
Australia	2	2	0.1
Hong Kong	2	2	8.3
Italy	1	1	0.0
United Kingdom	1	1	0.0
Belgium	1	1	0.1
Israel	1	1	0.1

## Flashback Nov 2021


South African researchers worked with GISAID and BII to characterize and track Omicron

BII was also part of WHO taskforce for the variant naming scheme.



# Live dashboard for choosing which emerging variants to investigate


- Fast spread (increase in observed locations)
- Number of relevant spike changes (with experimentally known effect or known Ab site)



List of literature references

AA Change	Virus Type	Mutation In Paper	Effect
Spike Y145H	Human SARS-CoV-2	L452R	Antibody binding

**Literature**





Reference

<https://www.rcsb.org/structure/7c2l>

<https://www.rcsb.org/structure/7cwu>

<https://pubmed.ncbi.nlm.nih.gov/34711101/>



**Sortable table**

variants in a 3-month period

in different time period. Hover over information to see detailed display of metadata.

October 2021

**Variants - Current Month**

Variant	Literature Ref   World Map   3D Structure	#Genomes	#Top Location	#Top Clade	#Top Lineage	Co-occurring Changes	#Co-occurring Changes	Δ#Loc(S)	#aachanges(C)	(SxC)
145H_452R_478K_681R	24798	17142	24767	23836	Spike_A222V, Spike_T19R, Spike_E156G, Spike_D950N	28	44	4	176	
452R_478K_681R_1263L	1563	457	1559	400	AY.4.2, B.1.617.2	25	31	4	124	
143X_144X_145X_146X_147X_148X_150X	24	6	24	14	B.1.617.2	15	10	7	70	
145H_152L_452R_478K_681R	33	10	33	33	AY.4.2	29	13	5	65	
132A_452R_478K_681R	60	22	59	50	AY.46	28	16	4	64	
47X_503X_504X	136	20	136	38	AY.43	28	18	3	54	
250I_346K_452R_478K_681R	29	9	29	29	AY.33	31	10	5	50	

Combining relevant changes found by CoVsurver with GISAID real-time genome counts across the world allows to track and find **Emerging Variants**.


This informs CEPI, UKHSA and WHO on new trends.



POWERING DISCOVERIES

# Conclusion

Our A\*STAR team has worked day and night for over 2 years as pillar of GISAID and in Singapore's COVID response



GISAID is a global data science initiative that involves public-private partnerships made possible by the GISAID community

We gratefully acknowledge all data contributors, i.e. the Authors and their Originating laboratories responsible for obtaining the specimens, and their Submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is based.

Thank You

4,377,478 sequences with complete collection date information shared via GISAID since 28 August 2021.

